GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Therapeutics Co Ltd (XKRX:115450) » Definitions » Price-to-Owner-Earnings

HLB Therapeutics Co (XKRX:115450) Price-to-Owner-Earnings : (As of Jun. 04, 2024)


View and export this data going back to 2010. Start your Free Trial

What is HLB Therapeutics Co Price-to-Owner-Earnings?

As of today (2024-06-04), HLB Therapeutics Co's share price is ₩7630.00. HLB Therapeutics Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for HLB Therapeutics Co's Price-to-Owner-Earnings or its related term are showing as below:

During the past 13 years, the highest Price-to-Owner-Earnings of HLB Therapeutics Co was 239.41. The lowest was 68.88. And the median was 144.32.


XKRX:115450's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.035
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-04), HLB Therapeutics Co's share price is ₩7630.00. HLB Therapeutics Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ₩-19.23. Therefore, HLB Therapeutics Co's PE Ratio for today is At Loss.

As of today (2024-06-04), HLB Therapeutics Co's share price is ₩7630.00. HLB Therapeutics Co's EPS without NRI for the trailing twelve months (TTM) ended in was ₩-179.11. Therefore, HLB Therapeutics Co's PE Ratio without NRI for today is At Loss.

During the past 13 years, HLB Therapeutics Co's highest PE Ratio without NRI was 290.36. The lowest was 0.00. And the median was 149.32.


HLB Therapeutics Co Price-to-Owner-Earnings Historical Data

The historical data trend for HLB Therapeutics Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Therapeutics Co Price-to-Owner-Earnings Chart

HLB Therapeutics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 77.65

HLB Therapeutics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 77.65 -

Competitive Comparison of HLB Therapeutics Co's Price-to-Owner-Earnings

For the Biotechnology subindustry, HLB Therapeutics Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLB Therapeutics Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, HLB Therapeutics Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where HLB Therapeutics Co's Price-to-Owner-Earnings falls into.



HLB Therapeutics Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

HLB Therapeutics Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=7630.00/-139.16
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


HLB Therapeutics Co  (XKRX:115450) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


HLB Therapeutics Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of HLB Therapeutics Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Therapeutics Co (XKRX:115450) Business Description

Traded in Other Exchanges
N/A
Address
22F, Parkview Tower, 6, Jeongja-Dong, Bundang-Gu, Seongnam-si, 463-863, KOR, 463-811
HLB Therapeutics Co Ltd is a bio company that pursues first-in-class and innovates new drug development. With the development and validation of new drugs for various hard-to-treat disorders, HLB Therapeutics is becoming a global biopharmaceutical company focused on alleviating patient suffering.

HLB Therapeutics Co (XKRX:115450) Headlines

No Headlines